Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9339466-B2

Patent

Publication Date

2016-05-17

Expiration Date


Abstract

Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Core Innovation

The content describes ST-246 polymorph Form I as a monohydrate identified by a characteristic X-ray powder diffraction pattern with specific reflection peaks. The disclosure reports powder X-ray diffraction traces, comparative diffraction patterns, and annotated FTIR spectra that support the identification of Form I. It also reports isolated-form purity, pharmaceutical compositions containing the polymorph, and oral capsule formulations.

The content further describes dissolution profiles over 0–60 minutes, faster dissolution for smaller Form I particles, and an ST-246 concentration-time profile over 72 hours. It reports preparation of Form I [procedural detail omitted for safety] and reliable production at greater than 99% purity. The polymorph is characterized as thermodynamically stable and non-hygroscopic, while the background and problem solved are not explicitly described in patent.

Claims Coverage

The claims identify one independent claim comprising one inventive feature directed to ST-246 polymorph Form I distinguished by characteristic X-ray powder diffraction peaks.

ST-246 polymorph Form I characterized by X-ray powder diffraction

The independent claim covers polymorph Form I of ST-246 characterized by an X-ray powder diffraction pattern having specified characteristic reflection peaks.

The independent claim defines ST-246 polymorph Form I by its characteristic diffraction pattern, while dependent claims add purity limitations, pharmaceutical compositions for oral administration, and a production method [procedural detail omitted for safety].

Stated Advantages

Form I is reported to be thermodynamically stable and non-hygroscopic.

The form is reported to be reliably produced at greater than 99% purity.

Smaller Form I particles are reported to provide faster dissolution.

Documented Applications

Form I is used in pharmaceutical compositions comprising one or more pharmaceutically acceptable ingredients and formulated for oral administration, including oral capsules.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.